You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)特瑞普利單抗注射液期中分析達主要研究終點 將遞上市申請
阿思達克 09-29 10:03
君實生物(01877.HK)公布,特瑞普利單抗注射液聯合化療治療復發性或轉移性鼻咽癌的隨機、雙盲、安慰劑對照、國際多中心的III期臨床研究在期中分析中,由獨立數據監察委員會(IDMC)判定達到了預設的主要研究終點。研究結果表明,特瑞普利單抗注射液聯合吉西他濱/順鉑一線治療復發性或轉移性鼻咽癌患者,較吉西他濱/順鉑的標準一線治療,可顯著延長患者的無進展生存期。

公司將於近期向國家藥品監督管理局及相關國家藥監部門遞交上市申請。(el/k) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account